Ricevi le ultime notizie sulle azioni Akebia Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di AKBA

Ultime notizie per

AKEBIA THERAPEUTICS INC

Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Reid Hoffman Warns Silicon Valley Blind Spot Could Fuel Next AI Revolution In Healthcare And Biology

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ACHC

AKBA

ALVO

L&#39;indicatore RSI segnala tre titoli ai minimi di 52 settimane. L&#39;eccesso di vendite potrebbe aver creato un&#39;opportunità unica.

3 azioni sanitarie che potrebbero esplodere nel mese di novembre

Akebia Therapeutics Inc

AKBANK T/A/S S/ADR by Akbank Turk Anonim Sirketi

Akbank TAS

AKBANK T/A/S GDR 144A by Akbank Turk Anonim Sirketi

Press Releases

General

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Absci

ADC Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Emergent BioSolutions

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Gossamer Bio

Immuneering Corporation - Class A Common Stock

Immuneering

Inventiva S.A. - American Depository Shares

Inventiva

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Keros Therapeutics

Lexeo Therapeutics

Monopar Therapeutics

Myriad Genetics

NovaBridge Biosciences - American Depositary Shares

NovaBridge Biosciences

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Organogenesis Holdings

Prothena Corporation plc - Ordinary Shares

Comments

Akebia Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO